Literature DB >> 8094062

Taxol sensitizes human ovarian cancer cells to radiation.

A Steren1, B U Sevin, J Perras, R Angioli, H Nguyen, L Guerra, O Koechli, H E Averette.   

Abstract

Taxol is an exciting antineoplastic agent with a novel mechanism of action. This study was designed to explore the potential use of taxol as a radiation sensitizer. Three human ovarian cancer cell lines were used: BG-1, SKOV-3, and OVCAR-3. These cell lines were treated in the proliferative and confluent state with taxol doses of 0.0001X, 0.0005X, 0.001X, 0.005X, and 0.01X peak plasma concentration of taxol for 90 min and then irradiated either 24 or 48 hr later. Doses of cobalt60 were 0, 2, 5, 8, and 10 Gy. ATP bioluminescence assays were performed on Day 7 after irradiation. Survival data was fit to the linear-quadratic model and mean inactivation dose D was calculated. Data analysis with t test and analysis of variance was performed. Taxol was found to have a significant radiosensitizing effect on all cell lines. Proliferating cells were more sensitive to taxol, radiation, and the combination than confluent cells. Treatment of proliferating cells with taxol 48 hr prior to irradiation had a greater radiosensitizing effect than treatment 24 hr prior to irradiation. In summary, taxol is a potent radiosensitizer in ovarian cancer cell lines and should be considered for further study.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8094062     DOI: 10.1006/gyno.1993.1043

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  6 in total

1.  The effect of paclitaxel on the radiosensitivity of gynecological tumor cells.

Authors:  M Rave-Fränk; H Meden; A Jäschke; A Tänzer; O Boghun; R Fietkau
Journal:  Strahlenther Onkol       Date:  1997-05       Impact factor: 3.621

2.  Enhanced efficacy of combined 213Bi-DTPA-F3 and paclitaxel therapy of peritoneal carcinomatosis is mediated by enhanced induction of apoptosis and G2/M phase arrest.

Authors:  Mario Vallon; Christof Seidl; Birgit Blechert; Zhoulei Li; Klaus-Peter Gilbertz; Anja Baumgart; Michaela Aichler; Annette Feuchtinger; Florian C Gaertner; Frank Bruchertseifer; Alfred Morgenstern; Axel K Walch; Reingard Senekowitsch-Schmidtke; Markus Essler
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-08-08       Impact factor: 9.236

3.  Assessment of effect of photosensitizers on cytotoxicity of photodynamic therapy in human breast cancer cell cultures.

Authors:  O R Koechli; G N Schaer; V Schenk; U Haller; H Walt
Journal:  Arch Gynecol Obstet       Date:  1995       Impact factor: 2.344

4.  Phase I study of paclitaxel (taxol) and granulocyte colony stimulating factor (G-CSF) in patients with unresectable malignancy.

Authors:  A I Einzig; P H Wiernik; S Wadler; J Kaplan; L T Benson; L Tentoramano; V Tan
Journal:  Invest New Drugs       Date:  1998       Impact factor: 3.850

5.  Differences in radiosensitivity between three HER2 overexpressing cell lines.

Authors:  Ann-Charlott Steffen; Lovisa Göstring; Vladimir Tolmachev; Stig Palm; Bo Stenerlöw; Jörgen Carlsson
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-01-12       Impact factor: 9.236

Review 6.  Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer.

Authors:  C M Spencer; D Faulds
Journal:  Drugs       Date:  1994-11       Impact factor: 9.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.